IRadimed Corporation (IRMD) Hit 52-Week High

June 29, 2018 - By James Macaulay

IRadimed Corporation (NASDAQ:IRMD) Logo

Investors sentiment decreased to 0.93 in 2018 Q1. Its down 1.64, from 2.57 in 2017Q4. It worsened, as 4 investors sold IRadimed Corporation shares while 10 reduced holdings. 4 funds opened positions while 9 raised stakes. 1.77 million shares or 9.50% more from 1.61 million shares in 2017Q4 were reported.
Bancorporation Of Mellon Corporation has 15,432 shares for 0% of their portfolio. Dimensional Fund Advsr Limited Partnership accumulated 10,885 shares. Moreover, Connors Investor has 0.07% invested in IRadimed Corporation (NASDAQ:IRMD) for 33,000 shares. Northern Trust stated it has 0% of its portfolio in IRadimed Corporation (NASDAQ:IRMD). Eam Lc accumulated 29,426 shares. Federated Invsts Pa has invested 0% in IRadimed Corporation (NASDAQ:IRMD). Bnp Paribas Arbitrage stated it has 0% of its portfolio in IRadimed Corporation (NASDAQ:IRMD). Cadence Capital Ltd Liability, Massachusetts-based fund reported 112,529 shares. Royal Savings Bank Of Canada has invested 0% in IRadimed Corporation (NASDAQ:IRMD). Macquarie Grp invested 0% of its portfolio in IRadimed Corporation (NASDAQ:IRMD). Stone Ridge Asset Mgmt Limited Company owns 26,141 shares. Massachusetts-based Adage Cap Ptnrs Gru Limited Co has invested 0% in IRadimed Corporation (NASDAQ:IRMD). The United Kingdom-based Barclays Public Ltd Company has invested 0% in IRadimed Corporation (NASDAQ:IRMD). Wells Fargo And Com Mn has 0% invested in IRadimed Corporation (NASDAQ:IRMD). Blackrock invested in 43,493 shares.

Since March 15, 2018, it had 1 buying transaction, and 4 selling transactions for $1.18 million activity. Waldman Louis S. also sold $94,987 worth of IRadimed Corporation (NASDAQ:IRMD) on Friday, May 4. 1,000 IRadimed Corporation (NASDAQ:IRMD) shares with value of $13,850 were bought by Susi Roger E.. Another trade for 35,000 shares valued at $647,525 was sold by Casey Francis X..

The stock of IRadimed Corporation (NASDAQ:IRMD) hit a new 52-week high and has $20.86 target or 3.00 % above today’s $20.25 share price. The 6 months bullish chart indicates low risk for the $215.79M company. The 1-year high was reported on Jun, 29 by Barchart.com. If the $20.86 price target is reached, the company will be worth $6.47 million more.
The 52-week high event is an important milestone for every stock because it shows very positive momentum and is time when buyers come in. During such notable technical setup, fundamental investors usually stay away and are careful shorting or selling the stock.

The stock increased 1.25% or $0.25 during the last trading session, reaching $20.25. About 19,638 shares traded. IRadimed Corporation (NASDAQ:IRMD) has risen 122.29% since June 29, 2017 and is uptrending. It has outperformed by 109.72% the S&P500.

Analysts await IRadimed Corporation (NASDAQ:IRMD) to report earnings on July, 27. They expect $0.08 EPS, up 166.67 % or $0.05 from last year’s $0.03 per share. IRMD’s profit will be $852,504 for 63.28 P/E if the $0.08 EPS becomes a reality. After $0.07 actual EPS reported by IRadimed Corporation for the previous quarter, Wall Street now forecasts 14.29 % EPS growth.

Iradimed Corporation develops, manufactures, markets, and distributes magnetic resonance imaging compatible products, and related accessories and services in the United States and internationally. The company has market cap of $215.79 million. It offers MRI compatible intravenous (IV) infusion pump system with associated disposable IV tubing sets under the MRidium name; and MRI compatible patient vital signs monitoring system under the IRadimed name. It has a 160.71 P/E ratio. The firm also offers IV poles, wireless remote displays/controls, side car pump modules, dose error reduction systems, and SpO2 monitoring with sensors and accessories; iMagox MRI pulse oximeter; and iMagox MRI oximeter remote and display products.

IRadimed Corporation (NASDAQ:IRMD) Institutional Positions Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: